StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)

Wed, 17 Jun 2026 06:50:54 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $26.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).

The analyst commented: "This past week, we hosted our H.C. Wainwright KOL Investor Webinar available here, with an interventional gastroenterologist offering clinical perspectives on VOQUEZNA and decade-long patient experience including the treatment of erosive esophagitis, non-erosive GERD, and H. pylori infection. We specifically discussed the KOL’s utilization of Phathom’s FDA-approved first-in-class novel potassium competitive acid blocker (PCAB), VOQUEZNA (vonoprazan), as the first innovation in decades in the GERD space targeting heartburn relief associated with non-erosive GERD (NERD), the healing and maintenance of healing

Form 4 Phathom Pharmaceuticals, For: May 22 Filed by: Parikh Asit

Wed, 27 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26558391.html

Form 4 Phathom Pharmaceuticals, For: May 22 Filed by: Parikh Asit

Wed, 27 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26558391.html

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Fri, 22 May 2026 08:00:00 -0400

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:

Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MN
Date: Thursday, May 28, 2026
Management to participate in one-on-one meetings throughout the conference

Jefferies Global Healthcare Conference in New York, NY
Date: Wednesday, June 3, 2026
Fireside Chat: 12:15 pm EDT
Management to participate in

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Fri, 22 May 2026 08:00:00 -0400

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:

Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MN
Date: Thursday, May 28, 2026
Management to participate in one-on-one meetings throughout the conference

Jefferies Global Healthcare Conference in New York, NY
Date: Wednesday, June 3, 2026
Fireside Chat: 12:15 pm EDT
Management to participate in

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Parikh Asit

Thu, 21 May 2026 17:16:00 -0400
si-local-file:///var/storage/secattach/20260521/26536867.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Parikh Asit

Thu, 21 May 2026 17:16:00 -0400
si-local-file:///var/storage/secattach/20260521/26536867.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: COLA MICHAEL F

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535905.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: COLA MICHAEL F

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535905.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Schroeder Theodore R

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535907.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Schroeder Theodore R

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535907.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: KARBE FRANK

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535908.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: KARBE FRANK

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535908.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Topper James N

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535911.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Topper James N

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535911.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Stenhouse Mark

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535917.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Stenhouse Mark

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535917.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: FIELDS HEIDI

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535919.html

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: FIELDS HEIDI

Thu, 21 May 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260521/26535919.html

Form 8-K Phathom Pharmaceuticals, For: May 19

Thu, 21 May 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260521/26535032.html

Form 8-K Phathom Pharmaceuticals, For: May 19

Thu, 21 May 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260521/26535032.html

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Wed, 20 May 2026 08:00:00 -0400

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts

Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)

Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases,

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Wed, 20 May 2026 08:00:00 -0400

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts

Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)

Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases,

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Wed, 20 May 2026 08:00:00 -0400

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts

Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)

Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases,

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Wed, 20 May 2026 08:00:00 -0400

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts

Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)

Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases,